Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals

Stock Track

05/21

Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.

The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.

Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1116682247"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116682247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116682247?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116682247","market":"hk","top_or_hot":-1,"title":"Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals","media":"Stock Track","content":"<p>Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.</p><p>The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.</p><p>Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-21 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.</p><p>The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.</p><p>Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1116682247","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116682247","pubTimestamp":1779330773,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"个股追踪|Impact Therapeutics-B盘中暴跌5.18%受IPO后获利了结及基本面疲弱影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics listed on the Hong Kong Stock Exchange earlier this month, with its public offering oversubscribed by 2,282.4 times and surging 108.26% on the first day. Since then, the stock has retreated over 15% from its post-listing high as early investors lock in gains.Fundamentally, the company remains in a loss-making phase, reporting a net loss of approximately RMB 296 million for 2025 on revenue of only RMB 38.25 million, insufficient to cover its intensive R&D expenditures. This limited fundamental support for its elevated valuation appears to be compounding selling pressure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}